BRIEF-Phillips 66 Announces Refining Leadership Transition
Reuters2026/10/05 12:32Phillips 66 PSX.N: PHILLIPS 66 ANNOUNCES REFINING LEADERSHIP TRANSITION PHILLIPS 66 - RICH HARBISON TO RETIRE AS EVP REFINING EFFECTIVE DEC 31, 2026 PHILLIPS 66 - CHRIS CHANDLER TO JOIN AS STRATEGIC ADVISOR TO CEO EFFECTIVE OCT 6, 2026 PHILLIPS 66 - CHRIS CHANDLER TO BECOME EVP REFINING EFFECTIVE JAN 1, 2027 Source text: ID:nBw23jq35a Further company coverage: PSX.N
Phillips 66 PSX.N:
PHILLIPS 66 ANNOUNCES REFINING LEADERSHIP TRANSITION
PHILLIPS 66 - RICH HARBISON TO RETIRE AS EVP REFINING EFFECTIVE DEC 31, 2026
PHILLIPS 66 - CHRIS CHANDLER TO JOIN AS STRATEGIC ADVISOR TO CEO EFFECTIVE OCT 6, 2026
PHILLIPS 66 - CHRIS CHANDLER TO BECOME EVP REFINING EFFECTIVE JAN 1, 2027
Source text: ID:nBw23jq35a
Further company coverage: PSX.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
